For decades, checking blood sugar meant the same routine: a lancet, a test strip, a drop of blood, and a number that told you nothing about what happened an hour ago or what might happen next. That era is ending. As of mid-2026, two continuous glucose monitors are available over the counter in the United States, no prescription required, and the first to reach that milestone is already sitting on pharmacy shelves.
The Dexcom Stelo, a small adhesive patch worn on the back of the upper arm, reads glucose levels through interstitial fluid just beneath the skin and streams data to a smartphone app. Each sensor lasts up to 15 days. There are no fingersticks, no lancets, and no blood draws. The FDA cleared it in March 2024 through its De Novo regulatory pathway, making it the first continuous glucose monitor authorized for nonprescription sale to adults 18 and older who do not use insulin.
Dexcom began shipping the Stelo directly to consumers in the summer of 2024 and has since expanded availability to major pharmacy retailers. The device is priced at roughly $49 per month (or about $99 for a two-sensor starter kit), positioning it well below the out-of-pocket cost of most prescription CGMs. Abbott’s FreeStyle Libre 2, a competing sensor, received its own OTC clearance from the FDA in June 2024, broadening the market further.
Who the Stelo is built for
The FDA’s clearance targets a specific population: adults with type 2 diabetes managed through diet, exercise, or non-insulin medications, and adults with prediabetes who want real-time feedback on how their bodies respond to food, movement, and stress. That group numbers in the tens of millions in the U.S. alone. According to the Centers for Disease Control and Prevention, roughly 98 million American adults have prediabetes, and many people with type 2 diabetes manage the condition without insulin.
The Stelo is not intended for people with type 1 diabetes, anyone using insulin, or real-time insulin dosing decisions. Those populations face a higher risk of rapid, dangerous glucose swings and typically need devices with tighter clinical oversight and alarm thresholds calibrated for hypoglycemia.
The practical appeal is straightforward. A fingerstick meter captures a single number at a single moment. A CGM captures the arc: how glucose spiked after a bowl of rice, how it dropped during a 30-minute walk, how it crept up during a sleepless night. That rolling picture lets users spot patterns they would never catch with two or three daily fingersticks.
What the research supports
Continuous glucose monitoring has a deep evidence base in insulin-using populations. Multiple randomized controlled trials have shown that CGM use reduces time spent in hyperglycemia and improves HbA1c levels among people with type 1 and insulin-treated type 2 diabetes. The technology’s value for non-insulin-using type 2 patients and people with prediabetes is less established but growing.
A 2023 study published in JAMA Internal Medicine found that CGM use among non-insulin-treated type 2 diabetes patients was associated with modest improvements in glycemic control over 12 months compared to traditional blood glucose monitoring. Researchers noted that the benefit appeared strongest when paired with behavioral coaching or structured lifestyle programs, raising the question of whether the sensor alone changes outcomes or whether it works best as part of a broader support system.
Dexcom submitted accuracy data to the FDA as part of the De Novo review. The agency determined the Stelo met its safety and effectiveness standards for the indicated population. Dexcom has reported a mean absolute relative difference (MARD) of approximately 8-9% for its G7 platform, which shares core sensor technology with the Stelo, though the company notes the two products are distinct. Independent, peer-reviewed accuracy studies specific to the Stelo’s OTC use case remain limited as of June 2026.
The cost and coverage question
At roughly $49 per month without insurance, the Stelo is cheaper than most prescription CGMs at their list prices but still represents a recurring expense that not every household can absorb. For comparison, a basic fingerstick glucometer and a month’s supply of test strips can cost as little as $15 to $30 at many pharmacies.
Because the Stelo is classified as an over-the-counter product, it does not follow standard prescription reimbursement pathways. Most private insurers, Medicare, and Medicaid plans do not currently cover OTC glucose monitors. Some health savings accounts (HSAs) and flexible spending accounts (FSAs) may allow the purchase, but coverage varies by plan. Dexcom offers a subscription model through its website, and some pharmacy chains have begun stocking the device alongside other OTC health monitors.
Abbott’s entry into the OTC CGM space could push prices lower over time. Competition between two established sensor manufacturers, both selling directly to consumers, creates downward pressure that did not exist when CGMs were available only through prescriptions.
What buyers should know before purchasing
An OTC glucose monitor is not a diagnostic tool. The Stelo does not diagnose diabetes or prediabetes, and a single high or low reading does not, on its own, mean a person needs medication. The FDA’s clearance language is specific: the device is meant to help users and their clinicians make better-informed decisions about diet, exercise, and lifestyle.
That distinction matters because the potential audience extends well beyond people with diagnosed metabolic conditions. Social media and wellness marketing have fueled broad interest in “metabolic health” tracking among people with normal glucose regulation. While there is nothing inherently harmful about a healthy person wearing a CGM, the clinical value of doing so is unproven, and the risk of misinterpreting normal glucose fluctuations as problems is real. Blood sugar naturally rises after meals and varies throughout the day. Without context, those swings can cause unnecessary anxiety.
For people with prediabetes or diet-managed type 2 diabetes, the most useful first step after buying a Stelo is a conversation with a primary care provider or endocrinologist. A clinician can help interpret early data, set personalized glucose targets, and establish thresholds for when a reading should prompt a call, a visit, or a change in routine. The sensor generates the data; a care team helps make it actionable.
Where OTC glucose monitoring goes from here
The Stelo’s arrival on pharmacy shelves marks a structural shift in how glucose data reaches consumers. For the first time, a person can walk into a drugstore, pick up a medical-grade glucose sensor, and start tracking their blood sugar the same afternoon, no appointment, no copay negotiation, no prior authorization. Abbott’s OTC entry doubles the options.
What remains to be seen is whether that access translates into better health outcomes at a population level. The clinical trials that built the case for CGMs were conducted in supervised settings with motivated participants and regular follow-up. Real-world OTC use will look different: buyers will include people with varying levels of health literacy, different relationships with their care teams, and different reasons for wanting the data.
Post-market surveillance will be critical. The FDA monitors cleared devices through its adverse event reporting system (MAUDE), and both Dexcom and Abbott are expected to track user complaints and sensor malfunctions. But the OTC model introduces a new variable: users who may not have a clinician to call when a reading confuses or alarms them. How manufacturers and pharmacies fill that gap, through app-based guidance, customer support lines, or partnerships with telehealth providers, will shape whether OTC CGMs become a lasting tool for metabolic health or a short-lived consumer trend.
The technology works. The regulatory path is open. The sensors are on the shelf. The harder question, whether millions of new users will know what to do with the numbers on their screens, is the one that matters most now.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
